MORRISTOWN, N.J.--(BUSINESS WIRE)--Alitair Pharmaceuticals, Inc., a clinical stage pharmaceutical company with multiple respiratory product candidates in development, today announced that it has received a second patent from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formulation of benzonatate, benzonatate polacrilex. The new patent, 8,808,743, contains a composition of matter claim covering the use of Alitair’s ion exchange formulation of benzonatate. The new patent also contains claims for using benzonatate polacrilex to reduce or eliminate the choking hazard associated with conventional liquid formulations of benzonatate.
Help employers find you! Check out all the jobs and post your resume.
